- Conditions
- Bleeding, Colorectal Disorders, Thromboembolism, Tranexamic Acid
- Interventions
- Tranexamic acid
- Drug
- Lead sponsor
- Kristen Ban
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Type 1 Diabetes, Hypoglycemia, Hyperglycaemia Due to Type 1 Diabetes Mellitus, Menstruation Disturbances
- Interventions
- Personalized modifications to treatment to address menstrual cycle effects on glycemia
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Ischemic Stroke, Stroke, Brain Infarction
- Interventions
- Eptifibatide, rt-PA
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 20
- States / cities
- Los Angeles, California • San Diego, California • Santa Monica, California + 11 more
- Conditions
- Postoperative Delirium, Hemodynamic Instability, Pain, Neurocognitive Dysfunction
- Interventions
- EEG Monitoring, Ropivacaine, Ketamine, Remifentanil, Dexmedetomidine, Rocuronium, Propofol
- Device · Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Myelogenous Leukemia, Chemotherapy-induced Nausea and Vomiting
- Interventions
- Ondansetron, Palonosetron
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Soft Palate
- Interventions
- LI, Cyclophosphamide, Indomethacin, Zinc, Surgery, Cisplatin, Radiotherapy
- Biological · Drug · Dietary Supplement + 2 more
- Lead sponsor
- CEL-SCI Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 928 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 5
- States / cities
- Springfield, Illinois • Detroit, Michigan • Cincinnati, Ohio + 2 more
- Conditions
- Advanced or Metastatic CRC
- Interventions
- Hydroxytyrosol
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Knee Disease, Knee Infection
- Interventions
- [F-18]MHF
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Congestive Heart Failure, Cardiac Transplantation, Renal Insufficiency, Renal Failure
- Interventions
- Natrecor (nesiritide)+Standard Care+dobutamine or milrinone, Placebo+Standard Care+dobutamine or milrinone
- Drug
- Lead sponsor
- Scios, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 14
- States / cities
- Stanford, California • Tampa, Florida • Chicago, Illinois + 11 more
- Conditions
- Pancreatitis
- Interventions
- Aggressive Intravenous Hydration Group, Standard Fluids Arm
- Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Blood Loss, Surgical, Blood Loss Anemia
- Interventions
- Tranexamic Acid
- Drug
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Arthroplasty
- Interventions
- Continuous Adductor Canal Block, General, Epidural, Spinal
- Procedure
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Bladder Cancer
- Interventions
- standard fluid management, fluid management guided by the EV1000
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 2 more
- Conditions
- Colonic Neoplasms
- Interventions
- Normal (0.9%) saline, HalfLytely
- Drug
- Lead sponsor
- Arya, Vijaypal, M.D., P.C.
- Individual
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 133 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Middle Village, New York
- Conditions
- Blood Loss
- Interventions
- Tranexamic Acid, Aquamantys System, Control
- Drug · Device · Other
- Lead sponsor
- Eastern Maine Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Bangor, Maine
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection, Questionnaire Administration, Radium Ra 223 Dichloride
- Procedure · Other · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Bozeman, Montana • Seattle, Washington + 1 more
- Conditions
- Brain Metastases, Brain Cancer
- Interventions
- 18F-Fluciclovine
- Drug
- Lead sponsor
- Baptist Health South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Rib Fractures
- Interventions
- ESP block with catheter using ropivacaine (bolus followed by continuous infusion), Lidocaine bolus (1 mg/kg) and infusion starting at 1 mg/kg/h
- Procedure · Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- Panitumumab, Indium In 111 Panitumumab, Single Photon Emission Computed Tomography, Computed Tomography, Surgical Procedure, Imaging agent, Intraoperative Imaging, Near Infrared Imaging, Electrocardiography, Biospecimen Collection
- Biological · Other · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Atherosclerosis, Acute Coronary Syndrome (ACS)
- Interventions
- Cangrelor, clopidogrel, Placebo bolus & placebo infusion, Placebo capsules - end of PCI, Placebo capsules - end of infusion
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- PostTraumatic Stress Disorder
- Interventions
- GammaCore/electroCore non-invasive VNS device, Sham gammaCore/electroCore, O-15 water
- Device · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Colorectal Disorders
- Interventions
- Exparel, IV Lidocaine
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Non-hodgkin Lymphoma, Hodgkin Lymphoma
- Interventions
- Sirolimus, Methotrexate, Tacrolimus, Cyclosporine, MMF
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Minneapolis, Minnesota + 1 more
- Conditions
- Magnetic Resonance Angiography, Contrast Media
- Interventions
- Standard Injection Rate, Patient Tailored Injection Rate, gadolinium contrast
- Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington